Presenter: Brent Hanks, MD, PhD, Assistant Professor of Medicine, Duke Cancer Institute
The March 2017 FDA approval of avelumab, a PD-L1 checkpoint inhibitor, for patients with metastatic Merkel cell carcinoma (MCC) provides a new treatment option for this rare skin cancer. Review the current treatment algorithm and clinical evidence supporting immunotherapies in MCC patients. Learn about other immuno-oncology agents in development, and the potential challenges and concerns related to metastatic MCC.
View On-Demand Webinar Download Slides